^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF inhibitor

    Related drugs:
    1m
    Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    1m
    A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC (clinicaltrials.gov)
    P2, N=60, Completed, Zhejiang Cancer Hospital | Not yet recruiting --> Completed | Trial completion date: Sep 2027 --> Aug 2025
    Trial completion • Trial completion date • Checkpoint inhibition
    |
    Idafang (ivonescimab)
    1m
    A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=348, Not yet recruiting, Akeso
    New P2 trial
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Idafang (ivonescimab)
    1m
    A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Shandong Cancer Hospital and Institute
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive
    |
    Idafang (ivonescimab)
    2ms
    SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Not yet recruiting, Sinocelltech Ltd.
    New P1/2 trial
    2ms
    SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=410, Recruiting, Sinocelltech Ltd.
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    2ms
    Sodium hyaluronate/lysine nanoparticles loaded with si-VEGF-A inhibits corneal neovascularization. (PubMed, Am J Transl Res)
    This study has confirmed that V-SH/Lys nanoparticles, by targeting and regulating VEGF-A, provide an efficient, safe and non-invasive treatment strategy for CNV, and have potential for clinical application.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    2ms
    A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=472, Not yet recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial • First-in-human
    2ms
    Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Idafang (ivonescimab)
    2ms
    OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    Idafang (ivonescimab)
    2ms
    OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Idafang (ivonescimab)
    2ms
    Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol). (PubMed, Transl Lung Cancer Res)
    Concurrently, recombinant human endostatin (Endostar) induces tumor vascular normalization and alleviates immunosuppression by inhibiting regulatory T cells (Tregs)...The study is registered in ClinicalTrials. gov (NCT06047860).
    P2 data • Journal
    |
    IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2)
    |
    Endostar (recombinant human endostatin)